SensoDetect (SDET) Q4 2025 earnings summary

Executive summary

• Strengthened operations in China through expanded collaborations and completed first investment round in the Beijing Mind Exploration Medical Technology JV.

• Transitioned to consolidated group reporting from Q3 2025, including new subsidiaries in Hong Kong and Shenzhen.

• Ended distribution agreement with Xiamen Encheng Group due to lack of product approval in China.

• Leadership changes: Johan Möllerström resigned as chairman, replaced by Pia Kinhult (interim), then Karl Vilhelm Gustaf Lundin.

• Focused on regulatory, clinical, and technical development in Europe, Middle East, and China.

Financial highlights

• Q4 2025 net sales: 1,143 KSEK; full year 2025: 2,322 KSEK.

• Q4 2025 result after financial items: -2,953 KSEK; full year 2025: -9,819 KSEK.

• Q4 2025 cash flow from operations: -2,113 KSEK; full year: -403 KSEK.

• Cash and cash equivalents at year-end: 1,966 KSEK; equity ratio: 78%.

• Q4 2025 operating expenses: -5,011 KSEK, mainly due to expansion and increased consulting and marketing costs.

Outlook and guidance

• 2026 focus on regulatory processes, technical completion, and commercial opportunities with strategic partners.

• Ongoing MDR transition in the EU to ensure long-term market access.

• Continued clinical activities in the Middle East and operational development in China.